You are here

Clinical Trials: Cord Blood

Condition:   Leukemia, Myeloid
Interventions:   Drug: IV Thiotepa;   Drug: IV Fludarabine;   Drug: IV Busulfan;   Drug: IV Anti-thymocyte globuline
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting
Condition:   Acute Myeloid Leukemia
Interventions:   Drug: chemotherapy (Mitoxantrone, Cytarabine);   Drug: Placebo;   Drug: Crenolanib;   Other: Allogeneic stem cell transplantation
Sponsor:   University of Ulm
Recruiting - verified March 2017
Condition:   Mesenchymal Stromal Cells
Intervention:   Drug: pneumostem
Sponsor:   Samsung Medical Center
Completed - verified April 2017
Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2017
Condition:   Hematological Malignancies
Interventions:   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Biological: G-CSF;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Drug: Methylprednisolone;   Radiation: Total lymphoid irradiation;   Biological: Lymphocyte infusions;   Device: CliniMACS
Sponsor:   St. Jude Children's Research Hospital
Recruiting - verified August 2016
Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting
Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting
Condition:   Severe Combined Immunodeficiency
Interventions:   Biological: unrelated BM with T cell depletion;   Biological: unrelated cord blood;   Biological: haplo BM with T cell depletion;   Device: unrelated PBSC with T cell depletion
Sponsor:   Neena Kapoor, M.D.
Terminated
Conditions:   Sickle Cell Disease;   Sickle Cell Anemia;   SCD
Interventions:   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplant (HSCT)
Sponsor:   Case Comprehensive Cancer Center
Recruiting - verified July 2017
Condition:   Alzheimer's Disease
Interventions:   Biological: human umbilical cord blood derived mesenchymal stem cells;   Other: Normal saline 2mL
Sponsor:   Medipost Co Ltd.
Recruiting - verified April 2017

Pages